Halozyme Therapeutics, Inc. HALO was a big mover last session, as the company saw its shares rise almost 8% on the day. The stock rallied after Piper Jaffray raised its price target on the stock from $15 to $18 on "increased conviction" in the long-term value of the San Diego-based biotech's company’s products, after an investor meeting with Halozyme’s management. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $9.42 to $11.10 in the past one-month time frame.
In the last 30 days, the company has seen no estimate revision and the Zacks Consensus Estimate also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Halozyme Therapeutics currently carries a Zacks Rank #3 (Hold), while its Earnings ESP is 0.00%.
A better-ranked Medical/Biomedical-Gene stock is ANI Pharmaceuticals, Inc. ANIP, which sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is HALO going up? Or down? Predict to see what others think: Up or Down
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Zacks Investment Research